藥敏試驗指導下個體化治療方案治療脊柱結核的臨床療效分析
發(fā)布時間：2018-11-20 12:15
【摘要】：目的分析我院脊柱結核耐藥情況及研究脊柱結核在藥敏試驗指導下的個體化抗結核藥物治療方案的臨床療效。 方法2010年01月至2011年08月對60例脊柱結核患者實施手術治療,術中收集膿液、肉芽組織,進行常規(guī)處理后接種至L-J(Lowenstein-Jensen改良羅氏培養(yǎng)基),陽性者進行抗酸染色,明確為結核分枝桿菌屬,再接種至L-J培養(yǎng)基,進行藥物敏感試驗測定,根據藥物敏感測試結果,參照耐藥結核藥物使用原則,制定出個體化抗結核藥物治療方案。1.藥敏測試結果為耐多藥結核,選用其它敏感的一線藥物和靜脈注射的二線敏感藥物,組成5聯抗癆方案。2.藥敏測試結果只對原治療方案中一種藥物耐藥者,將該藥物更換為另一敏感的一線殺菌藥或靜脈注射的二線敏感藥物；3.細菌培養(yǎng)結果為陰性、藥敏測試結果無耐藥或對原治療藥物均敏感者,繼續(xù)原治療方案。定期隨訪,觀察患者的全身情況和局部情況,結合X、CT片、ESR(Erythrocyte sedimentation rate血沉),評價結核治愈及椎間植骨融合情況。 結果培養(yǎng)標本60例,有34例培養(yǎng)陽性,陽性率為56.7%(34/60)。出現耐藥的有11例,耐藥率為18.3%(11/60),其中耐多藥的1例(同時耐利福平和異煙肼),耐多藥率為1.67%(1/60)。利福平耐藥率為1.67%(1/60),異煙肼耐藥率為3.33%(2/60),左氧氟沙星耐藥率為3.33%(2/60),卡那霉素耐藥率為6.67%(4/60),鏈霉素耐藥率為8.33%(5/60)。對耐多藥的1例患者將利福平和異煙肼更換為卷曲霉素、左氧氟沙星和卡那霉素繼續(xù)治療,3個月后停用卡那霉素,共完成療程18個月；對單耐異煙肼的1例患者將異煙肼更換為左氧氟沙星,完成療程18個月；對耐左氧氟沙星、卡那霉素、鏈霉素的9例患者繼續(xù)原治方案,完成療程18個月；對培養(yǎng)結果陰性的26例和藥敏測試結果為全敏感的23例患者繼續(xù)原治方案,完成療程18個月。對耐藥的11例患者進行隨訪,術后3個月全部患者的局部癥狀和結核中毒癥狀消失,術后6個月血沉恢復正常,術后18個月,椎間植骨均為4-5級骨性融合,術前有神經癥狀的5例患者中有3例神經功能完全恢復,1例獲得改善,結核均無復發(fā)。 結論本地區(qū)脊柱結耐藥率為18.3%,耐多藥率為1.67%。藥敏測試指導下制定個體化治療方案治療脊柱結核的療效更確切,值得臨床推廣運用。
[Abstract]:Objective to analyze the drug resistance of spinal tuberculosis in our hospital and to study the clinical effect of individualized antituberculous drug therapy under the guidance of drug sensitivity test. Methods from January 2010 to August 2011, 60 patients with spinal tuberculosis received surgical treatment. The pus and granulation tissue were collected during the operation and then inoculated into L-J (Lowenstein-Jensen modified Roche medium) after routine treatment. The positive patients were stained with acid-fast. For Mycobacterium tuberculosis, then inoculated into L-J medium, drug sensitivity test was carried out. According to the results of drug sensitivity test and referring to the principle of drug resistant TB drug use, the individualized anti-tuberculosis drug treatment scheme was worked out. 1. The results of drug sensitivity test were multidrug resistant tuberculosis. Other sensitive first-line drugs and intravenous second-line sensitive drugs were selected to form a 5-linked anti-tuberculosis regimen. 2. Drug sensitivity test results only to the original treatment of one drug resistance, the drug will be replaced by another sensitive first-line bactericidal drug or intravenous injection of second-line sensitive drug; 3. The results of bacterial culture were negative, the drug sensitivity test results were not resistant or sensitive to the original treatment drugs, continue the original treatment plan. The patients were followed up regularly to observe the whole body and local condition, combined with, ESR (Erythrocyte sedimentation rate erythrocyte sedimentation rate (ESR), to evaluate the cure of tuberculosis and the fusion of intervertebral bone graft. Results the positive rate of culture was 56.7% (34 / 60). The drug resistance rate was 18.3% (11 / 60) in 11 cases, including 1 case of multidrug resistance (both rifampicin and isoniazid), and the multidrug resistance rate was 1.67% (1 / 60). Rifampicin resistance rate was 1.67% (1 / 60), isoniazid resistance rate was 3.33% (2 / 60), levofloxacin resistance rate was 3.33% (2 / 60), kanamycin resistance rate was 6.67% (4 / 60). Streptomycin resistance rate was 8.33% (5 / 60). Rifampicin and isoniazid were replaced by rifampicin and isoniazid as capriamycin, levofloxacin and kanamycin were continued to be treated for 3 months, kanamycin was stopped after 3 months, and the course of treatment was 18 months. Isoniazid was replaced with levofloxacin for 18 months in one patient with isoniazid resistance, and 9 patients who were resistant to levofloxacin, kanamycin and streptomycin were treated with isoniazid for 18 months. 26 cases with negative culture results and 23 cases with full sensitivity test were treated with primordial therapy for 18 months. 11 patients with drug resistance were followed up. After 3 months, the local symptoms and tuberculosis poisoning symptoms of all the patients disappeared, and the ESR returned to normal at 6 months after operation. After 18 months, the intervertebral bone graft was 4-5 grade bone fusion. Of the 5 patients with neurological symptoms before operation, 3 cases recovered completely, 1 case improved and no recurrence of tuberculosis occurred. Conclusion the drug resistance rate of spinal node and multi-drug resistance in this area is 18. 3 and 1. 67 respectively. Under the guidance of drug sensitivity test, individualized treatment of spinal tuberculosis is more effective and worthy of clinical application.
【學位授予單位】：遵義醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2013
【分類號】：R529.2
本文編號：2344885
[Abstract]:Objective to analyze the drug resistance of spinal tuberculosis in our hospital and to study the clinical effect of individualized antituberculous drug therapy under the guidance of drug sensitivity test. Methods from January 2010 to August 2011, 60 patients with spinal tuberculosis received surgical treatment. The pus and granulation tissue were collected during the operation and then inoculated into L-J (Lowenstein-Jensen modified Roche medium) after routine treatment. The positive patients were stained with acid-fast. For Mycobacterium tuberculosis, then inoculated into L-J medium, drug sensitivity test was carried out. According to the results of drug sensitivity test and referring to the principle of drug resistant TB drug use, the individualized anti-tuberculosis drug treatment scheme was worked out. 1. The results of drug sensitivity test were multidrug resistant tuberculosis. Other sensitive first-line drugs and intravenous second-line sensitive drugs were selected to form a 5-linked anti-tuberculosis regimen. 2. Drug sensitivity test results only to the original treatment of one drug resistance, the drug will be replaced by another sensitive first-line bactericidal drug or intravenous injection of second-line sensitive drug; 3. The results of bacterial culture were negative, the drug sensitivity test results were not resistant or sensitive to the original treatment drugs, continue the original treatment plan. The patients were followed up regularly to observe the whole body and local condition, combined with, ESR (Erythrocyte sedimentation rate erythrocyte sedimentation rate (ESR), to evaluate the cure of tuberculosis and the fusion of intervertebral bone graft. Results the positive rate of culture was 56.7% (34 / 60). The drug resistance rate was 18.3% (11 / 60) in 11 cases, including 1 case of multidrug resistance (both rifampicin and isoniazid), and the multidrug resistance rate was 1.67% (1 / 60). Rifampicin resistance rate was 1.67% (1 / 60), isoniazid resistance rate was 3.33% (2 / 60), levofloxacin resistance rate was 3.33% (2 / 60), kanamycin resistance rate was 6.67% (4 / 60). Streptomycin resistance rate was 8.33% (5 / 60). Rifampicin and isoniazid were replaced by rifampicin and isoniazid as capriamycin, levofloxacin and kanamycin were continued to be treated for 3 months, kanamycin was stopped after 3 months, and the course of treatment was 18 months. Isoniazid was replaced with levofloxacin for 18 months in one patient with isoniazid resistance, and 9 patients who were resistant to levofloxacin, kanamycin and streptomycin were treated with isoniazid for 18 months. 26 cases with negative culture results and 23 cases with full sensitivity test were treated with primordial therapy for 18 months. 11 patients with drug resistance were followed up. After 3 months, the local symptoms and tuberculosis poisoning symptoms of all the patients disappeared, and the ESR returned to normal at 6 months after operation. After 18 months, the intervertebral bone graft was 4-5 grade bone fusion. Of the 5 patients with neurological symptoms before operation, 3 cases recovered completely, 1 case improved and no recurrence of tuberculosis occurred. Conclusion the drug resistance rate of spinal node and multi-drug resistance in this area is 18. 3 and 1. 67 respectively. Under the guidance of drug sensitivity test, individualized treatment of spinal tuberculosis is more effective and worthy of clinical application.
【學位授予單位】：遵義醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2013
【分類號】：R529.2
【參考文獻】
相關期刊論文 前10條
1 華春珍,虞燕萍;結核桿菌的耐藥機制[J];國外醫(yī)學(流行病學傳染病學分冊);2001年05期
2 馬李,葉冬青;IEC在結核病防治中的應用及發(fā)展前景[J];國外醫(yī)學.流行病學傳染病學分冊;2005年04期
3 W.W.Yew;徐彩紅;何廣學;;結核分枝桿菌耐藥機制[J];國際結核病與肺部疾病雜志(中文版);2009年04期
4 陳俊林;顧德林;顧欣榮;施軍衛(wèi);石彩芳;;MPB64抗原檢測快速診斷結核分枝桿菌的臨床價值[J];臨床肺科雜志;2010年03期
5 徐東芳;王慶;;BacT/ALERT 3D在結核分枝桿菌快速培養(yǎng)和藥敏試驗中的應用[J];臨床輸血與檢驗;2011年01期
6 吳雪瓊;;結核分枝桿菌分子生物學研究的現狀及展望[J];實用醫(yī)學雜志;2010年23期
7 王法正;李毛召;阿不力克木·阿不都熱西提;張克遠;;胸腰椎結核前路病灶清除單純植骨或內固定療效比較[J];新疆醫(yī)科大學學報;2008年03期
8 許鵬雍;凌尚準;;脊柱結核的外科治療進展[J];右江民族醫(yī)學院學報;2010年05期
9 李大偉;馬遠征;侯英;薛海濱;黃鳳山;;耐藥脊柱結核的外科治療[J];中國骨傷;2010年07期
10 吳啟秋,潘毓萱,畢志強,鄧立宏,那希寬;骨關節(jié)結核病灶中耐多藥結核分枝桿菌對療效的影響[J];中華骨科雜志;2005年07期
，本文編號：2344885
本文鏈接：http://sikaile.net/yixuelunwen/chuanranbingxuelunwen/2344885.html
最近更新
教材專著
